C12N 2770/28033
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/28033 (Use of viral protein as therapeutic agent other than vaccine) appears on 5 US grants and 5 published applications in this corpus.
Search patents in C12N- Granted patents
- 5
- Published applications
- 5
- Assignees
- 2
- Inventors
- 2
- Latest grant
- 29 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 1 | 1 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
| 2024 | 1 | 1 |
| 2025 | 1 | 0 |
By publication year.
Recent patents
- Compositions and methods for antigen targeting to CD18029 Jul 2025US 12,371,672 B2University of Washington
- Compositions and methods for antigen targeting to CD18025 Jun 2024US 12,018,291 B2University of Washington
- Compositions and methods for antigen targeting to CD18010 Jan 2023US 11,549,102 B2University of Washington
- Compositions and methods for antigen targeting to CD18018 Feb 2020US 10,563,179 B2University of Washington through its Center for Commercialization
- Compositions and methods for antigen targeting to CD1805 Feb 2019US 10,196,614 B2University of Washington through its Center for Commercialization
- Compositions and Methods for Antigen Targeting to CD18012 Sep 2024US 2024/0301364 A1University of Washington
- Compositions and Methods for Antigen Targeting to CD18013 Apr 2023US 2023/0113073 A1University of Washington
- Compositions and Methods for Antigen Targeting to CD1809 Jul 2020US 2020/0216819 A1University of Washington
- Compositions and Methods for Antigen Targeting to CD18016 May 2019US 2019/0144834 A1University of Washington through its Center for Commercialization
- Compositions and Methods for Antigen Targeting to CD18027 Aug 2015US 2015/0238630 A1University of Washington through its Center for Commercialization
Most cited
By later US patents
- Compositions and methods for antigen targeting to CD1806US 10,196,614 B2University of Washington through its Center for Commercialization · 2019
- Compositions and methods for antigen targeting to CD1805US 10,563,179 B2University of Washington through its Center for Commercialization · 2020
- Compositions and methods for antigen targeting to CD1802US 11,549,102 B2University of Washington · 2023
- Compositions and methods for antigen targeting to CD1801US 12,018,291 B2University of Washington · 2024